Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease

被引:4
作者
Santos-Lobato, Bruno Lopes [1 ,2 ]
Borges, Vanderci [3 ]
Ferraz, Henrique Ballalai [3 ]
Mata, Ignacio Fernandez [4 ,5 ]
Zabetian, Cyrus P. [4 ,5 ]
Tumas, Vitor [1 ,2 ]
机构
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav Sci, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil
[2] Univ Sao Paulo, Ctr Res Support Appl Neurosci NAPNA, Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Neurol, Sao Paulo, SP, Brazil
[4] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA
[5] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
来源
NITRIC OXIDE-BIOLOGY AND CHEMISTRY | 2018年 / 74卷
关键词
Dyskinesia; Parkinson's disease; Levodopa; Nitric oxide; NOS1; gene; QUALITY-OF-LIFE; RATING-SCALE; MOTOR FLUCTUATIONS; C276T POLYMORPHISM; RISK-FACTORS; INHIBITOR; IMPACT; NNOS; NOS1;
D O I
10.1016/j.niox.2017.06.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Levodopa-induced dyskinesia (LID) is a common complication of advanced Parkinson's disease (PD). PD physiopathology is associated with dopaminergic and non-dopaminergic pathways, including the nitric oxide system. The present study aims to examine the association of a neuronal nitric oxide synthase gene (NOS1) single nucleotide polymorphism (rs2682826) with LID in PD patients. Methods and results: We studied 186 PD patients using levodopa. The presence of LID was defined as a MDS-UPDRS Part IV score >= 1 on item 4.1. We tested for association between NOS1 rs2682826 and the presence, daily frequency, and functional impact of LID using regression models, adjusting for important covariates. There was no significant association between genotype and any of the LID-related variables examined. Conclusions: Our results suggest that this NOS1 polymorphism does not contribute to LID susceptibility or severity. However, additional studies that include a comprehensive set of NOS1 variants will be needed to fully define the role of this gene in LID. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:86 / 90
页数:5
相关论文
共 44 条
[1]  
[Anonymous], STAT PARK DIS
[2]   Clinical Spectrum of Levodopa-Induced Complications [J].
Aquino, Camila Catherine ;
Fox, Susan H. .
MOVEMENT DISORDERS, 2015, 30 (01) :80-89
[3]   Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap [J].
Calabresi, Paolo ;
Di Filippo, Massimiliano ;
Ghiglieri, Veronica ;
Tambasco, Nicola ;
Picconi, Barbara .
LANCET NEUROLOGY, 2010, 9 (11) :1106-1117
[4]   Impact of the motor complications of Parkinson's disease on the quality of life [J].
Chapuis, S ;
Ouchchane, L ;
Metz, O ;
Gerbaud, L ;
Durif, F .
MOVEMENT DISORDERS, 2005, 20 (02) :224-230
[5]  
Cui H., 2010, BIOL PSYCHIAT, V16, P992
[6]  
Del-Bel Elaine, 2015, Front Biosci (Elite Ed), V7, P168
[7]   Counteraction by Nitric Oxide Synthase Inhibitor of Neurochemical Alterations of Dopaminergic System in 6-OHDA-Lesioned Rats Under L-DOPA Treatment [J].
Del-Bel, Elaine ;
Padovan-Neto, Fernando Eduardo ;
Szawka, Raphael Escorsim ;
da-Silva, Celia Aparecida ;
Raisman-Vozari, Rita ;
Anselmo-Franci, Janete ;
Romano-Dutra, Angelica Caroline ;
Guimaraes, Francisco Silveira .
NEUROTOXICITY RESEARCH, 2014, 25 (01) :33-44
[8]   Nitric oxide synthase inhibitor improves de novo and long-term L-DOPA-induced dyskinesia in hemiparkinsonian rats [J].
Eduardo Padovan-Neto, Fernando ;
Bermudez Echeverry, Marcela ;
Chiavegatto, Silvana ;
Del-Bel, Elaine .
FRONTIERS IN SYSTEMS NEUROSCIENCE, 2011, 5
[9]  
Fahn S., 1987, Recent Dev. Parkinsons Dis, P153, DOI DOI 10.2490/JJRMC.47.791
[10]   Neuronal nitric oxide synthase (NOS1) and its adaptor, NOS1AP, as a genetic risk factors for psychiatric disorders [J].
Freudenberg, F. ;
Alttoa, A. ;
Reif, A. .
GENES BRAIN AND BEHAVIOR, 2015, 14 (01) :46-63